Pharmacokinetics and safety of plasma-derived factor XIII concentrate (human) in patients with congenital factor XIII deficiency

Haemophilia

Volumn 21, Issue 1, 2015, Pages 95-101

  Nugent, D J ^a   Ashley, C ^b   Garcia Talavera J ^c   Lo, L C ^d   Mehdi, A S ^e   Mangione, A ^f  

^a CHILDREN S HOSPITAL OF ORANGE COUNTY   (United States)

^b Alabama Clinical Therapeutics   (United States)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^e Stockton Hematology Oncology Medical Group Inc   (United States)

^f CSL BEHRING   (United States)

Author keywords

Bleeding disorders; Coagulation; Congenital factor XIII deficiency; Factor XIII; Pharmacokinetics; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 13 CONCENTRATE; BLOOD CLOTTING FACTOR 13; PHARMACOLOGICAL BIOMARKER;

ADOLESCENT; ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING FACTOR 13 DEFICIENCY; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG CLEARANCE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; FEMALE; HUMAN; MALE; MULTICENTER STUDY; OPEN STUDY; PRIORITY JOURNAL; PROPHYLAXIS; STEADY STATE; TREATMENT DURATION; VOLUME OF DISTRIBUTION AT STEADY-STATE; CHILD; CLINICAL TRIAL; FACTOR XIII DEFICIENCY; PRESCHOOL CHILD; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS, PHARMACOLOGICAL; CHILD; CHILD, PRESCHOOL; FACTOR XIII; FACTOR XIII DEFICIENCY; FEMALE; HUMANS; MALE; YOUNG ADULT;

EID: 84921603836     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/hae.12505     Document Type: Article

References (21)

1. Anwar R, Miloszewski KJ. Factor XIII deficiency. Br J Haematol 1999; 107: 468-84.
2. Nugent DJ. Prophylaxis in rare coagulation disorders - factor XIII deficiency. Thromb Res 2006; 118(Suppl. 1): S23-8.
3. Karimi M, Bereczky Z, Cohan N, Muszbek L. Factor XIII deficiency. Semin Thromb Hemost 2009; 35: 426-38.
4. Anwar R, Minford A, Gallivan L, Trinh CH, Markham AF. Delayed umbilical bleeding-a presenting feature for factor XIII deficiency: clinical features, genetics, and management. Pediatrics 2002; 109: E32.
5. Hsieh L, Nugent D. Factor XIII deficiency. Haemophilia 2008; 14: 1190-200.
6. CSL Behring. Corifact. Highlights of Prescribing Information. Available at http://www.corifact.com/docs/Corifact-Prescribing-Information.pdf. Accessed May, 2014.
7. CSL Behring. Fibrogammin Summary of Product Characteristics. Available at http://www.medicines.org.uk/emc/medicine/405/SPC/Fibrogammin+P/. Accessed May, 2014.
8. National Hemophilia Foundation. MASAC Recommendations Concerning Products Licensed for the Treatment of Hemophilia and Other Bleeding Disorders. Available at https://www.hemophilia.org/sites/default/files/document/files/masac190.pdf. Accessed May, 2014.
9. Bolton-Maggs PH, Perry DJ, Chalmers EA et al. The rare coagulation disorders-review with guidelines for management from the United Kingdom Haemophilia Centre Doctors' Organisation. Haemophilia 2004; 10: 593-628.
10. Muszbek L, Bagoly Z, Cairo A, Peyvandi F. Novel aspects of factor XIII deficiency. Curr Opin Hematol 2011; 18: 366-72.
11. Brackmann HH, Egbring R, Ferster A et al. Pharmacokinetics and tolerability of factor XIII concentrates prepared from human placenta or plasma: a crossover randomised study. Thromb Haemost 1995; 74: 622-5.
12. Peyvandi F, Palla R, Menegatti M. Rare Bleeding Disorders (RBDs) - a European Response. Available at http://www.rbdd.eu/imag/books/ENGLISH.pdf. Accessed May, 2014.
13. Raut S, Merton RE, Rigsby P et al. A collaborative study to establish the 1st International Standard for factor XIII plasma. J Thromb Haemost 2007; 5: 1923-9.
14. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE). Available at http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed May, 2014.
15. Fickenscher K, Aab A, Stuber W. A photometric assay for blood coagulation factor XIII. Thromb Haemost 1991; 65: 535-40.
16. Lovejoy AE, Reynolds TC, Visich JE et al. Safety and pharmacokinetics of recombinant factor XIII-A2 administration in patients with congenital factor XIII deficiency. Blood 2006; 108: 57-62.
17. Anderson BJ, Holford NH. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet 2009; 24: 25-36.
18. Manco-Johnson MJ, Dimichele D, Castaman G et al. Pharmacokinetics and safety of fibrinogen concentrate. J Thromb Haemost 2009; 7: 2064-9.
19. Williams M, Will A, Stenmo C, Rosholm A, Tehranchi R. Pharmacokinetics of recombinant factor XIII in young children with congenital FXIII deficiency and comparison with older patients. Haemophilia 2014; 20: 99-105.
20. Ajzner E, Muszbek L. Prophylactic and perioperative replacement therapy for acquired factor XIII deficiency: a rebuttal. J Thromb Haemost 2004; 2: 2075-7.
21. Lusher J, Pipe SW, Alexander S, Nugent D. Prophylactic therapy with Fibrogammin P is associated with a decreased incidence of bleeding episodes: a retrospective study. Haemophilia 2010; 16: 316-21.